Site Resource Center
Xaluritamig is a novel investigational T-cell engager immunotherapy being developed for advanced prostate cancer. Xaluritamig is designed to activate the immune system against prostate cancer cells by creating an immune synapse between immune T cells and STEAP1, a protein that is uniquely overexpressed in prostate cancer cells.1-3
The resources below are intended to support the XALute Study staff.